GSK (GSK) Earnings Analysis

GSK (GSK) next reports earnings on 2026-07-28, consensus EPS 1.27 USD. Last quarter (2026-04-29) it beat with EPS 1.24 USD vs 1.16 USD est (+6.9%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E 13.11.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GSK next report earnings?

Next earnings date2026-07-28
Consensus EPS estimate1.27 USD
Revenue estimate11.02B

GSK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-291.24 USD1.16 USD+6.9%Beat
2026-02-040.68 USD0.64 USD+6.3%Beat
2025-10-291.48 USD1.26 USD+17.5%Beat
2025-07-301.23 USD1.12 USD+9.8%Beat
2025-04-301.13 USD1.08 USD+4.6%Beat
2024-10-301.27 USD1.16 USD+9.5%Beat
2024-07-311.09 USD1 USD+9%Beat

Beat rate: 7/7 (100%) over reported quarters with consensus data.

GSK valuation and analyst view

Trailing P/E13.11
Trailing EPS2.9 USD
Price / book4.28
Dividend yield3.52%
Market cap101.87B
Analyst consensusHold (9 buy / 16 hold / 4 sell)
Avg price target53 USD

Related research pages

Frequently asked questions

When is GSK (GSK)'s next earnings date?

GSK is next scheduled to report on 2026-07-28, with a consensus EPS estimate of 1.27 USD and revenue estimate of 11.02B.

Did GSK beat earnings last quarter?

In its 2026-04-29 report, GSK posted EPS of 1.24 USD versus a 1.16 USD estimate — a beat of 6.9%.

What is GSK's earnings track record?

Over the last 7 reported quarters with consensus data, GSK beat estimates 7 times (100%).

What is GSK's current P/E ratio and EPS?

GSK trades at a trailing P/E of 13.11 on trailing EPS of 2.9 USD.

What do analysts rate GSK?

Analyst consensus is "Hold" across 29 ratings (0 strong buy, 9 buy, 16 hold, 4 sell, 0 strong sell). Average 12-month price target: 53 USD.